Recommended Alerts

Sign Up For Alerts

The End of an Era: How Will Terminating the COVID-19 Public Health Emergency Affect Life Sciences Companies?

The Biden Administration recently announced that it would allow the COVID-19 public health emergency (“PHE”) to expire on May 11, 2023. Coming more than three years after the Secretary of the U.S. Department of Health and Human Services (“HHS”) declared the PHE, the decision not to renew the emergency declaration will directly affect multiple stakeholders in the health care system, including life sciences companies.

Read More

2022 Enforcement Review for FDA-Regulated Products: Back to Basics

Time to Read: 1 minutes Practices: FDA Regulatory Industries: Healthcare & Life Sciences

Printer-Friendly Version

As the COVID-19 public health emergency has slowly receded from the headlines, the U.S. Food and Drug Administration (“FDA”) and its enforcement partner, the Department of Justice (“DOJ”), have spent much of the past year focused on traditional areas of enforcement, including manufacturing practices, product safety, data integrity, and the removal of unapproved products from the market. Although we expect enforcement action in connection with COVID-19-related fraud to continue, FDA appears highly motivated to clear its inspection backlog and ramp up enforcement for manufacturing and data integrity-related deficiencies. Industry stakeholders would be well advised to ensure their compliance infrastructures are appropriately focused on core FDA issues like product quality and ensuring appropriate product approval prior to marketing.

This 2022 enforcement review highlights key trends and developments relating to enforcement that may be of interest to FDA-regulated companies when considering risks in 2023, including:

  • A renewed focus on food safety
  • A continuing emphasis on drug quality and current good manufacturing practices (“cGMPs”)
  • The invocation of rarely used medical device authorities
  • The viability of FDA’s authority over certain stem cell products
  • A new FDA focus on product fulfillment platforms
  • Continued scrutiny of clinical trial fraud
  • More aggressive enforcement against noncompliant tobacco products
  • New DOJ expectations for post-resolution compliance in actions involving alleged violations of the Federal Food, Drug, and Cosmetic Act (“FDCA”).

Printer-Friendly Version

Cookie Settings